SeaStar Medical Holding Corporation (ICU) - Net Assets
Based on the latest financial reports, SeaStar Medical Holding Corporation (ICU) has net assets worth $11.46 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($15.53 Million) and total liabilities ($4.07 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of SeaStar Medical Holding Corporation to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $11.46 Million |
| % of Total Assets | 73.82% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
SeaStar Medical Holding Corporation - Net Assets Trend (2020–2024)
This chart illustrates how SeaStar Medical Holding Corporation's net assets have evolved over time, based on quarterly financial data. Also explore total assets of SeaStar Medical Holding Corporation for the complete picture of this company's asset base.
Annual Net Assets for SeaStar Medical Holding Corporation (2020–2024)
The table below shows the annual net assets of SeaStar Medical Holding Corporation from 2020 to 2024. For live valuation and market cap data, see SeaStar Medical Holding Corporation stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-2.18 Million | +84.26% |
| 2023-12-31 | $-13.87 Million | +33.20% |
| 2022-12-31 | $-20.76 Million | -637.29% |
| 2021-12-31 | $-2.82 Million | +96.07% |
| 2020-12-31 | $-71.58 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to SeaStar Medical Holding Corporation's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6784800000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | % |
| Other Components | $137.38 Million | % |
| Total Equity | $-2.18 Million | 100.00% |
SeaStar Medical Holding Corporation Competitors by Market Cap
The table below lists competitors of SeaStar Medical Holding Corporation ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Morenzo Abadi Perkasa Tbk Pt
JK:ENZO
|
$9.12 Million |
|
Ranplan Group
ST:RPLAN
|
$9.13 Million |
|
Megado Minerals Ltd
AU:MEG
|
$9.14 Million |
|
RKEC Projects Limited
NSE:RKEC
|
$9.14 Million |
|
Revenue Group Bhd
KLSE:0200
|
$9.12 Million |
|
Jwwinvest
WAR:JWW
|
$9.11 Million |
|
Nagreeka Exports Limited
NSE:NAGREEKEXP
|
$9.11 Million |
|
Chemomab Therapeutics Ltd DRC
NASDAQ:CMMB
|
$9.11 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SeaStar Medical Holding Corporation's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -13,870,000 to -2,183,000, a change of 11,687,000.
- Net loss of 24,830,000 reduced equity.
- New share issuances of 17,441,000 increased equity.
- Other factors increased equity by 19,076,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-24.83 Million | -1137.43% |
| Share Issuances | $17.44 Million | +798.95% |
| Other Changes | $19.08 Million | +873.84% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares SeaStar Medical Holding Corporation's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | $-1372.27 | $4.37 | x |
| 2021-12-31 | $-53.98 | $4.37 | x |
| 2022-12-31 | $-398.24 | $4.37 | x |
| 2023-12-31 | $-160.01 | $4.37 | x |
| 2024-12-31 | $-5.83 | $4.37 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SeaStar Medical Holding Corporation utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -18392.59%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is below the historical average (0.00%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $3.88 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.31 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-20.94 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-24.84 Million |
| 2024 | 0.00% | -18392.59% | 0.03x | 0.00x | $-24.61 Million |
Industry Comparison
This section compares SeaStar Medical Holding Corporation's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $44,828,400
- Average return on equity (ROE) among peers: -124.18%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SeaStar Medical Holding Corporation (ICU) | $11.46 Million | 0.00% | 0.35x | $9.12 Million |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-54.64 Million | 0.00% | 0.00x | $118.88 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $3.60 Million | -91.89% | 0.28x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $266.97 Million | -19.62% | 0.16x | $171.87 Million |
| Abpro Holdings, Inc. (ABP) | $3.07 Million | -479.81% | 1.57x | $448.19K |
| Absci Corp (ABSI) | $67.00 Million | -21.42% | 0.32x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $88.00 Million | -44.09% | 0.34x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $80.00K | -31.70% | 0.38x | $26.41 Million |
| Abivax SA American Depositary Shares (ABVX) | $40.58 Million | -434.26% | 4.06x | $9.33 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $23.36 Million | -97.44% | 0.37x | $3.74 Billion |
About SeaStar Medical Holding Corporation
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hy… Read more